Transcriptional control by androgens via androgen receptor (AR) is strongly involved in prostate cancer development, but the critical target genes have remained elusive. We have characterized E twenty-six-like transcription factor 4 (ELK4) (also known as serum response factor accessory protein 1) as a novel AR target in human prostate cancer cells. In-silico screening identified three putative AR response elements (AREs) within À10 kb from the transcription start site of ELK4. Both ARE1 at À167/À153 and ARE2 at À481/À467 bound AR in vitro and mediated androgen induction as isolated elements in transcription assays in non-prostate cells. However, merely the ARE2 that cooperates with a proximal forkhead box A1-binding site was critical for the ARdependent activation of ELK4 promoter in prostate cancer cells. Preferential loading of holo-AR onto the ARE2 and concomitant recruitment of RNA polymerase II onto the ELK4 promoter was confirmed in prostate cancer cells by chromatin immunoprecipitation. Database searches indicated that the expression of ELK4 is markedly increased in prostate cancers relative to normal prostates. Moreover, prostate cancer tissue immunostainings showed that nuclear ELK4 levels are significantly increased in androgen-refractory prostate cancers compared to untreated tumours. Reduction of the amount of ELK4 in LNCaP cells by RNAi retarded cell growth. In conclusion, ELK4 is a direct AR target in prostate cancer cells. Androgens may thus contribute to the growth of prostate cancer via influencing ELK4 levels.
Introduction
Androgens have a key role in male sexual development and act via androgen receptor (AR) that belongs to the nuclear receptor superfamily. Androgens have a crucial role in development of prostate cancer, which is the most widespread neoplasm in men in Western countries. Androgen-dependency was first recognized by Huggins and Hodges (1941) , who showed that the removal of androgens leads to regression of prostate cancer (Culig et al., 2002; Heinlein and Chang, 2004) . Therefore androgen ablation therapy is used to delay cancer development, but the therapy fails eventually and cancer turns into a hormone-refractory disease (Stewart et al., 2005) . The mechanism how prostate cancer transforms from an androgen-dependent to an androgen-independent stage is incompletely understood (Feldman and Feldman, 2001) .
Forced overexpression of AR can transform androgen-dependent prostate cancer cells to androgenindependent ones (Chen et al., 2004) . In concordance to these experimental findings, common amplification and overexpression of AR is associated with hormonerefractory clinical prostate cancer specimens (Visakorpi et al., 1995; Linja et al., 2001) . Also overexpression of AR co-activators has been implicated in progression of prostate cancer grade, stage and decreased disease-free survival, but the results are inconsistent (Gregory et al., 2001; Culig et al., 2004; Linja et al., 2004) . Mutations and polymorphisms in the AR gene may also play a role in the development of prostate cancer (Han et al., 2005) . For example, mutations in the ligand-binding domain of the AR have been found in prostate cancers treated with antiandrogens, such as flutamide (Taplin et al., 1995) .
Only a small number of androgen-responsive genes have been well characterized in prostate cancer cells. The best studied gene is prostate-specific antigen (PSA) that is a member of kallikrein (KLK) gene family (Riegman et al., 1991) . The level of PSA protein in plasma is important for prostate cancer diagnostics and monitoring prostate cancer state (Maroni and Crawford, 2006) . PSA (KLK3) contains two AR response elements (AREs) in its proximal promoter (PSAprom) and a more distal ARE unit/enhancer, with the latter AR-binding unit being more important for the androgen response (Cleutjens et al., 1996 (Cleutjens et al., , 1997 Schuur et al., 1996) . Recently, about half of the prostate cancers were shown to contain genetic rearrangements leading to fusion of transmembrane protease, serine 2 (TMPRSS2) gene and either ERG, ETV1 or ETV4 gene that encode E twenty-six (ETS) transcription factors. The most common form of these fusions is TMPRSS2:ERG. ERG is a putative oncogene whose expression is low in nonmalignant prostate, whereas TMPRSS2 is highly expressed in prostate. The expression of TMPRSS2 is androgen-regulated, and therefore, the TMPRSS2:ERG rearrangement leads to androgen-dependent and abundant expression of the fusion transcript in prostate cancer cells. These genetic alterations have given first hints at the strong androgen dependence of prostate cancer development (Tomlins et al., 2006) .
In this study, we have characterized androgendependent regulation of a novel AR target gene, ETSlike transcription factor 4 (ELK4), that belongs to the ternary complex factor (TCF) subfamily of ETS domain transcription factors (Dalton and Treisman, 1992; Shaw and Saxton, 2003; Buchwalter et al., 2004) . The latter factors were first described in the context of c-fos gene regulation (Shaulian and Karin, 2002; Buchwalter et al., 2004) . Interestingly, analysis of gene expression databases indicates that the expression of ELK4 is increased in prostate cancer. Moreover, we found that hormonerefractory prostate cancers contain significantly more ELK4 in their nuclei compared to androgen-sensitive prostate cancer specimens. We suggest that AR can influence prostate growth also via ELK4-regulated genes.
Results
Androgens induce ELK4 in prostate cancer cells As ETS domain transcription factor ELK4 has been recently listed among genes overexpressed in prostate cancer (Edwards et al., 2005) and as perturbed regulation of at least two other ETS factor genes EGR and ETV1 has been implicated in a significant number of prostate cancer samples (Tomlins et al., 2005 (Tomlins et al., , 2007 , we chose to analyse potential androgen regulation of ELK4 and the other closely related TCF genes ELK1 and ELK3 in LNCaP cells by employing quantitative RNA analysis with PSA as a reference gene. As shown in Figures 1c and d , PSA mRNA and also ELK4 mRNA accumulated in LNCaP cells in response to treatment with synthetic androgen R1881. First signs of mRNA induction were seen within 3 h after the addition of R1881, and the levels of the mRNAs continued to increase for at least next 15 h (PSA B7-fold (Po0.001) and ELK4 B5-fold (Po0.001) increase after 18 h). In contrast to ELK4 mRNA, neither ELK1 nor ELK3 mRNA was stimulated by R1881 (Figures 1a and b) . If anything, there was a modest decrease in their mRNA levels after androgen treatment. ELK4 mRNA was similarly (B4-fold, Po0.05) induced by R1881 in VCaP prostate cancer cells. Two ELK4 mRNA splice variants a and b have been reported (Dalton and Treisman, 1992) . Both of the ELK4 isoforms were induced by androgen in LNCaP cells with the accumulation of isoform a being somewhat more pronounced than that of isoform b ( Figure 1e ). As expected, androgen did not induce ELK4 in AR-deficient PC-3 prostate cancer cells (Figure 1f ). Moreover, there was a positive correlation between the expression level of ELK4 and the presence of functional AR in several other prostate cancer cell lines (Figure 1j ).
To test whether new protein synthesis is required for the hormonal induction of ELK4, LNCaP cells were treated with cycloheximide (CHX), a protein synthesis inhibitor, during the induction with R1881. Interestingly, CHX attenuated the androgen induction of ELK4 mRNA to about half, but it also decreased the induction of PSA mRNA, a classic direct androgen target gene, by B40% (Figure 1g) . Therefore, even though we cannot rule out the possibility that a labile androgen-induced protein is involved in the regulation of ELK4, we suggest that a major part of the androgen regulation occurs through a direct action of AR on the gene promoter. Moreover, since addition of actinomycin D, a transcription inhibitor, abolished the androgen induction of ELK4 mRNA in LNCaP cells (Figure 1h ), androgens act at the level of transcription rather than influencing the stability of ELK4 mRNA. Immunoblotting of LNCaP cell extracts with anti-ELK4 antibody showed that the amount of immunoreactive ELK4 is clearly increased after 12-h induction with R1881, which is in agreement with the mRNA data (Figure 1i ). were treated 18 h with 10 nM R1881 in the absence and presence of cycloheximide ( þ CHX, 10 mg/ml). (h) LNCaP cells were treated 18 h with 10 nM R1881 in the absence and presence of actinomycin D (1 mg/ml). Quantitative RT-PCR was used to measure the mRNA levels of ELK4 and PSA. Total RNA levels between samples were normalized using mRNA levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Fold changes were calculated using the formula 2 ÀðDDCtÞ , where DDC t is DC t(R1881) ÀDC t(EtOH) , DC t is C t(gene X) -C t(GAPDH) and C t is the cycle at which the threshold is crossed. Columns represent the mean of three experiments and bars indicate standard deviations. (i) Immunoblot analysis of ELK4 in LNCaP cells at indicated times after addition of R1881. The lower panel shows a-tubulin levels in the same samples. Representative gels of three experiments are shown. The protein lanes originate from the same experiment and analysis, but they have been regrouped as indicted by dividing lanes. (j) Quantitative RT-PCR analyses to measure the relative mRNA levels of ELK4 in indicated androgen receptor (AR)-positive (LNCaP(AR þ ) and LAPC4) and AR-negative (LNCaP(ARÀ), DU154 and PC-3) prostate cancer cell lines were carried out as described (Linja et al., 2004) .
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Identification of putative androgen response elements in the ELK4 promoter Next, we were interested in whether ELK4 is directly regulated by AR and revealing the regulatory elements mediating the regulation. We performed in-silico analysis up to À10 kb from the transcription start site of ELK4 using CONSITE program (http://mordor.cgb.ki. se/cgi-bin/CONSITE/consite) to identify potential AREs in the ELK4 promoter. The analysis suggested three putative AREs (ARE1-3) two of which (ARE1 and ARE2) are located in the PSAprom region and the third (ARE3) in the distal promoter (Figure 2a) . To test capability of the putative AREs to bind AR, we performed electrophoretic mobility shift assays (EMSAs) with AR produced by ectopic expression in COS-1 cells. The intronic ARE of the prostatic C3(1) gene that binds efficiently AR in vitro was used as a positive control (Kallio et al., 1994) . EMSAs showed that AR does not interact with ARE3, but the receptor is capable of binding to both ARE1 and ARE2, albeit less efficiently than to the positive control ARE (Figure 2b) . Quantification of the R1881-bound AR-DNA complexes (in the absence of antibodies) by phosphoimager analysis indicated that the intensity of AR-ARE1 complexes was about one-fifth (19 ± 1%) and that of AR-ARE2 complexes about one-tenth (9±2%) of the intensity of AR-C3(1)ARE complexes. To confirm that the observed DNA-protein complexes were caused by AR, not due to other AR-induced proteins in COS-1 cell lysates, we used anti-AR antibody in EMSA reactions. As shown in Figure 2b , ARE1-, ARE2-and C3(1)ARE-protein complexes were clearly upshifted in the presence of the anti-AR antibody, but not with a non-specific antibody, whereas ARE3 again showed no evidence for interaction with AR.
Loading of holo-AR to the ELK4 promoter in vivo To investigate protein occupancy of the chromatin regions bearing the ELK4 promoter in vivo, we performed chromatin immunoprecipitation (ChIP) using antibodies specific for AR and RNA polymerase II (PolII) with primer pairs covering ELK4 proximal (ELK4prom) and distal (ELK4dis) promoter ( Figure 2a ). LNCaP cells were treated with or without androgen for 120 min. After cross-linking and sonication, chromatin samples were immunoprecipitated with specific antibodies or immunoglobulin G (IgG) control, and recovered DNAs were used as templates in quantitative PCR. Promoter and enhancer regions of PSA served as positive controls (Figures 3a and b) . As shown in Figures 3c and d , loading of AR and recruitment of PolII onto the ELK4prom were clearly increased in response to androgen stimulation, whereas the occupancy of AR or that of PolII on ELK4dis was negligible in comparison to ELK4prom, also after the androgen treatment. Higher-resolution ChIP analyses with shorter chromatin fragments and additional primers showed that the region bearing ARE2 recruited AR more efficiently than that containing ARE1 (Figure 3e ). These ChIP data verify that holo-AR is loaded onto the ELK4 promoter under bona fide chromatin conditions. Functionality of the putative ELK4 AREs Next, we assessed the individual importance of the ARE1 and ARE2 in living cells by performing reporter gene assays (RGAs) with ELK4 promoter fragments cloned in front of luciferase gene (LUC) and used 5.8-kb PSA enhancer/promoter-driven luciferase (PSA5.8-LUC) as a positive control. The constructs were transfected to LNCaP cells and the cells were grown with or without androgen. ELK4 promoter fragment (À209/ þ 54) that contains only ARE1, yielded only a minor (o2-fold) increase in luciferase activity in the presence of androgen, whereas ELK4 promoter fragment (À543/ þ 54) containing both ARE1 and ARE2 conferred significant B11-fold (Po0.001) androgen induction in the LUC activity ( Figure 4a) . Surprisingly, a much longer ELK4 promoter fragment (À6086/ þ 54) yielded practically no androgen induction, suggesting that the upstream ELK4 region harbours elements capable of silencing the promoter. To further test the importance of ARE1 and ARE2 in the androgen induction, we mutated both AREs (ARE1m: AATAAAttaTGCTCT, ARE2m: GATACTgcaTTTTTC) individually or in combination in the context of the À543/ þ 54 promoter fragment. In line with the above (b) Electrophoretic mobility shift assays were performed in the presence of AR-containing COS-1 cell extracts (AR þ ) or extracts from empty vector-transfected cells (ARÀ), and 32 P-labelled dsAREs. Protein-DNA complexes were resolved on non-denaturing 4% polyacrylamide gels. Anti-AR antibody was used to confirm the specificity of AR-DNA complexes, and normal rabbit immunoglobulin G (IgG) (non-spec ab) was used as non-specific control. A representative gel of three experiments is shown.
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H Makkonen et al RGA data, mutation of the ARE2 alone (or in combination with the ARE1), but not that of the ARE1, abolished the androgen induction of ELK4 promoter in LNCaP cells (Figure 4a ). Also in VCaP prostate cancer cells that contain endogenous AR, merely ARE2 was sufficient for conferring androgen induction ( Figure 4b ). Similar results were obtained in PC-3 cells co-transfected with an AR expression construct, albeit the androgen induction of the promoter constructs was weaker in these cells than in the two ARpositive prostate cancer cells (Figure 4c ). Interestingly, the ELK4 promoter fragment À209/ þ 54 that showed practically no androgen induction in LNCaP cells was induced by androgen in a fashion comparable to that of the À543/ þ 54 construct in HeLa cervical carcinoma cells co-transfected with AR expression construct (Figure 4d ; B15-and B17-fold induction, respectively). In HeLa cells, both ARE mutations clearly attenuated the androgen effect, albeit the effect of ARE2 mutation was slightly more deleterious than that of ARE1 mutation. To test the functionality of ARE1 and ARE2 in isolation, we cloned individual AREs and their mutated versions in front of a TATA box-driven LUC and co-transfected those with AR expression vector to COS-1 cells. The C3(1)ARE-TATA construct was used as a positive control. In agreement with the EMSA data, the ELK4 ARE2 did not dramatically differ from the ELK4 ARE1 in conferring androgen induction in isolation, but they were both less active than the positive control ARE (Figure 4e ; B6-and B5-fold induction, respectively, vs 28-fold induction). Mutation of ARE1 or that of ARE2 practically abolished the androgen induction.
AR cooperates with FoxA1 in the regulation of ELK4 promoter The above reporter gene data imply cell specificity in the function of the ARE2 and involvement of other promoter binding and cooperating transcription factors. In-silico analyses predicted the presence of a forkhead box A1 (FoxA1)-binding site at À449/À438 in the close proximity of the ARE2. To test the importance of the putative FoxA1 site for the androgen induction of ELK4 promoter in prostate cancer cells, we changed the underlined Ts of the sequence À449 ATATGTTT GCAT À438 to the Gs in context of ELK4-543/ þ 54 promoter fragment and compared the activity of mutated fragment to that of the wild-type promoter fragment in conferring androgen induction. Interestingly, the mutation resulted in B50% reduction in the androgen induction of ELK4 promoter in LNCaP and VCaP cells, whereas, in non-prostate HeLa or COS-1 cells, it did not have any marked effect on the androgen induction ( Figure 5a) . Notably, the mutation of the FoxA1-binding site did not influence the activity of the Figure 2a) . (e) Differentiation of AR binding between the ELK4 AR response element (ARE) 2 and the ELK4 ARE1 using higher-resolution chromatin immunoprecipitation (ChIP) assays with shorter chromatin fragments and primer pairs that are selective for two the AREs (Supplementary Table S1 ). ChIP samples were used as templates in quantitative PCR. Enhancer (a) and promoter (b) regions of prostate-specific antigen (PSA) were used as references. Results are shown as percentages of the input samples. The percentages were calculated using the formula 2 ÀðDCtÞ Â100, where DC t is C t(ChIP-template) ÀC t(Input) . Columns represent the mean±s.d. of three experiments.
Regulation of
ELK4-543/ þ 54 promoter in the absence of androgen. ChIP assays with FoxA1-specific antibody indicated that in prostate cancer cells, the interaction of the FoxA1 with the ELK4 promoter is enhanced in the presence of androgen (Figure 5b) . To confirm the importance of FoxA1 in the regulation of ELK4, we silenced the FoxA1 by RNAi in LNCaP cells and studied the effect of silencing on androgen-induced accumulation of ELK4 mRNA. Silencing of GATA2 that has recently been implicated in the regulation of some AR target genes was used as an additional control . FoxA1 siRNA and GATA2 siRNA were similarly efficient in reducing their target protein levels ( Figure 5c ). As shown in Figure 5d , the androgen induction of ELK4 mRNA was severely compromised (Po0.001) in FoxA1-ablated cells in comparison to 
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GATA2-silenced cells or scrambled (SCR) control
siRNA-treated cells. These results strongly suggest that the cooperation between the ARE2 and the adjacent FoxA1 site is required for the androgen induction of the ELK4 in prostate cancer cells.
ELK4 influences LNCaP cell growth
Because of the potential involvement of ELK4 in cell growth, we attenuated its expression by RNAi in LNCaP cells and monitored the effect of the silencing on cell proliferation. To that end, we used ELK4-specific siRNAs that were designed and synthesized in a fashion that minimizes off-target effects (Jackson et al., 2006) . The two most potent ELK4 siRNAs decreased the amount of ELK4 mRNA levels in the absence of androgen by B85% and in the presence of androgen by B70% compared to control siRNA-treated levels, resulting in marked silencing effects on the ELK4 protein level (Figure 6a) . Interestingly, the growth of ELK4 siRNA-treated LNCaP cells was significantly retarded in the absence of androgen in comparison to the control siRNA-transfected cells (Po0.01 and Po0.05 for ELK4-1 and ELK4-2 siRNA, respectively, at 72 h; Po0.001 for both ELK4 siRNAs at 96 h) (Figure 6b ). Addition of androgen stimulated the cell growth, and also under these conditions, ELK4 siRNAs showed a tendency to inhibit cell proliferation. These data indicate that the ELK4 can contribute to the proliferation of LNCaP cells, especially under diminished levels of androgen. 
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Increased expression of ELK4 in prostate cancer
To reveal potential differences in the expression of ELK4 between normal and tumour prostate, we retrieved gene expression data from the Oncomine website (www.oncomine.org). Statistical analysis of the data from Yu et al. (2004) revealed that ELK4 expression is significantly increased in prostate cancer in comparison to non-malignant prostate, with metastatic cancer showing higher expression than locally occurring cancer (Figure 7a ). In addition, three other microarray studies display increased ELK4 levels in prostate cancer compared to normal prostate tissue (Luo et al., 2001; Magee et al., 2001; Welsh et al., 2001) .
We next wanted to analyse the cellular distribution of ELK4 protein in prostate samples using immunohistochemical analysis. As shown in Figure 7b , ELK4 localizes mainly to the epithelial cells in non-malignant prostate, with the nuclear compartment showing more intense immunoreactivity than the cytoplasm. We also examined whether the clinicopathological parameters and the ELK4 levels correlate in untreated and hormone refractory cancers. To that end, tissue microarrays corresponding to untreated prostate cancers and locally recurrent hormone-refractory prostate cancers were analysed with anti-ELK4 antibody, and nuclear and cytoplasmic stainings were scored separately. Although these analyses did not reveal an apparent correlation between ELK4 intensity and Gleason score, pT stage or PSA value in untreated tumours, immunostainings of the TMAs showed that in androgen-refractory prostate cancers, nuclear ELK4 levels are significantly (Po0.0001) increased in comparison to untreated tumours (Table 1) .
Discussion
ELK4 (SRF accessory factor-1, SAP-1) belongs to the TCF subfamily of the ETS domain transcription factors that are classic targets for mitogen-activated protein kinases (MAPKs). Other members in this subfamily are ELK1 and ELK3 (NET, SAP-2 or ERP). The TCFs bind and activate serum response elements together with serum response factor (SRF). The TCF-SRF complexes regulate many immediate early genes, such as c-fos, encoding a subunit of AP-1 (Shaulian and Karin, 2002; Shaw and Saxton, 2003; Buchwalter et al., 2004) . TCFs, especially ELK4 and ELK1, appear to have at least partly overlapping biological roles, which may explain the relatively subtle defects of Elk1(À/À) and Elk4(À/À) mice (Ayadi et al., 2001; Zheng et al., 2003; Cesari et al., 2004; Costello et al., 2004) . ELK1 and other ETS domain transcription factors ERG and PDEF have recently been implicated in the growth of prostate cancer cells (Oettgen et al., 2000; Xiao et al., 2002; Tomlins et al., 2005) . Interestingly, recent molecular concept modelling of prostate cancer progression showed strong enrichment of ELK1-binding sites in the promoters of genes overexpressed in prostatic intraepithelial neoplasia vs benign prostate (Tomlins et al., 2007) . Activation of TCFs in response to MAPK signalling is well characterized, but very little is known about their regulation by steroid hormones. Our results showing that ELK4, but not ELK1 or ELK3, is upregulated by androgens indicate that the TCFs are differentially regulated, even though they are likely to have overlapping roles in transcription regulation. In the absence of active MAPK signalling, ELK3/NET has been shown to act through its NET inhibitory domain (NID) and Cterminal-binding protein inhibition domain as a potent repressor of transcription (Buchwalter et al., 2004) . Since also ELK4 harbours an NID, it may similarly repress transcription in the absence of sustained growth factor stimulation.
In addition to direct genomic effects, androgens have been reported to regulate cell physiology indirectly via influencing protein kinase pathways and/or other transcription factors (Heinlein and Chang, 2002) . We therefore tested whether the androgen induction of ELK4 was conferred by direct binding of AR to the ELK4 promoter that was predicted to harbour three potential AREs. Two of the in silico-predicted AREs, ARE1 (at À167/À153) and ARE2 (at À481/À467), bound AR in vitro and both of them were functional in transcription assays in HeLa and COS-1 cells. However, in AR-positive prostate cancer cells, merely the ARE2 was capable of conferring the androgen induction of the ELK4 promoter, indicating cell type-specific differences 
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in the function of ELK4 AREs. These differences are due to cooperation between the ARE2 and its proximal FoxA1-binding site in prostate cancer cells. In addition to the binding of FoxA1, ChIP analyses verified the androgen-induced loading of AR and the recruitment of RNA polymerase II onto the ELK4 promoter under bona fide chromatin environment. Our results thus confirm that the ELK4 is directly regulated by the AR, but similarly to some other AR target genes in prostate cancer cells (Gao et al., 2003; Wang et al., 2007) , the receptor has to cooperate with another DNA-binding factor, FoxA1 to induce the ELK4 gene. The higher abundance of ELK4 in prostate as compared to most other human tissues (expressed sequence tag information at http://genome-www5.stanford.edu) suggests that it has an interesting role in the regulation of prostate physiology. Microarray data indicate that ELK4 expression is further increased in prostate cancers compared to non-malignant prostates (Oncomine database) (Edwards et al., 2005) . Our finding that the growth of LNCaP prostate cancer cells can be retarded by reducing the cellular ELK4 suggests that the protein promotes proliferation of prostate cancer cells. Recently, other ETS transcription factors, especially ERG, have been shown to be overexpressed in prostate cancers due to genetic rearrangements leading to androgen regulation of the ERG (Tomlins et al., 2005) . Since ELK4 itself is androgen-regulated, its enhanced expression in prostate cancer can take place without genetic alterations affecting ELK4. Our data showing that nuclear levels of ELK4 protein are significantly elevated in hormone-refractory tumours compared to untreated cancers further suggest that ELK4 could be an important contributor to the progression of prostate cancer.
Materials and methods
Cell culture
LNCaP, VCaP, HeLa, PC-3, COS-1, DU145 cells were obtained from American Type Culture Collection and maintained as described (Linja et al., 2004; Karvonen et al., 2006) . LAPC4 cells were kindly provided by Dr Charles Sawyers (UCLA).
DNA constructs
Promoter regions of ELK4 were PCR-amplified from human genomic DNA using Phusion DNA polymerase (Finnzymes, hormone-refractory PC Figure 7 Expression of E twenty-six (ETS)-like transcription factor 4 (ELK4) in prostate tumours. (a) Gene expression data of ELK4 were retrieved from the Oncomine website (www.oncomine.org), and the data from Yu et al. (2004) was used for statistical calculations. The data were re-analysed to show expression levels of ELK4 in benign prostate (BP), prostate carcinoma (PC), and metastatic prostate cancer (MPC). Horizontal lines represent medians. Difference of expression compared to median of BP group is shown in the y axis. P-values were calculated using unpaired one-way analysis of variance (ANOVA) and Bonferroni post hoc test. (b) Representative examples of benign prostate hyperplasia (BPH), untreated and hormone-refractory prostate cancer samples stained with anti-ELK4 antibody (see Supplementary Figure) . In non-malignant prostate, moderate anti-ELK4 immunoreactivity can be detected both in cytoplasmic and nuclear compartments.
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Espoo, Finland) and cloned into pGL3-basic (Promega, Madison, WI, USA). ARE-TATA constructs were produced by ligation of ds-oligomers into the TATA box-containing pGL3-basic. All sequences were verified by DNA sequencing using the ALFexpress system. pSG5-hAR and pPSA5.8-LUC have been described (Karvonen et al., 2006) . pCMV encoding b-galactosidase was from Clontech (Mountain View, CA, USA). Mutations were constructed with QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to manufacturer's instructions.
Antibodies
Primary antibodies anti-AR (sc-816), anti-ELK4 (anti-Sap1a) (sc-13030), anti-PolII (sc-899), anti-FoxA1 (sc-6553), anti-GATA2 (sc-9008), anti-a-tubulin (sc-5286) and normal rabbit IgG (sc-2027) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Secondary antibodies were purchased from Zymed (South San Francisco, CA, USA): Zymax goat antirabbit IgG (H þ L) horseradish peroxidase (HRP) conjugate (81-6120) and Zymax goat anti-mouse IgG (H þ L) HRP conjugate (81-6520).
Quantitative real-time RT-PCR LNCaP or PC-3 cells were seeded into six-well plates (330 000 cells per well) and grown 48 h in transfection medium (LNCaP: RPMI 1640, 5% charcoal-stripped fetal bovine serum (FBS) (CCS-FBS), 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 25 mM glucose; PC-3: F-12 (Ham), 5% CCS-FBS). Cells were treated with or without 10 nM R1881 (Perkin Elmer Inc., Waltham, MA, USA). Total RNA was extracted using TRIZOL reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and converted to cDNA using M-MuLV Reverse Transcriptase (Fermentas, Vilnius, Lithuania) following manufacturer's instructions. cDNA was used as a template in quantitative real-time PCR, which was carried out using M Â 3000P (Stratagene), ABsolute QPCR SYBR Green Mix (Abgene, Epson, UK) and specific primers (Supplementary Table S1 ).
Immunoblotting
LNCaP cells were seeded, grown and treated as prior to quantitative real-time RT-PCR. SDS PAGE and immunoblotting were carried out as described (Karvonen et al., 2006) . Antigen-antibody complexes were detected using ECL Plus western Blotting Detection System (GE Healthcare) according manufacturer's instructions.
Electrophoretic mobility shift assay For production of AR for EMSAs, COS-1 cells were transfected either with empty pSG5 or pSG5-hAR and cell extracts were prepared as described (Thompson et al., 2001) . Cell extract (12 mg) was used for 20-ml EMSA reaction and incubated with or without R1881 (10 nM) and specific antibody or normal rabbit IgG (200 ng) for 10 min at 22 1C before addition of 32 P-labelled ds-oligomer probe. Protein-DNA complexes were allowed to form for 1 h (Palvimo et al., 1993) . Probes contained the 29-bp native sequences (Supplementary Table S1 ). The complexes were separated on 4% non-denaturing PAGE. The gels were dried and detected using phosphoimager (FLA3000, Fuji).
Chromatin immunoprecipitation
The experiments were performed essentially as previously described . LNCaP cells were seeded resulting at B50% confluence and allowed to grow in transfection medium for 48 h before treating with 10 nM luminometer and b-galactosidase activity as described (Palvimo et al., 1993) .
RNAi and cell proliferation assays
For silencing of FoxA1 and GATA2, Qiagen custom siRNAs and control SCR were used. Target sequences for the FoxA1, GATA2 and SCR were 5 0 -GAGAGAAAAAATCAACAGC-3 0 , 5 0 -ACCCTTAGCAGCCCAGCAT-3 0 and 5 0 -AATTCTCC GAACGTGTCACGT-3 0 , respectively .
LNCaP cells were transfected with siRNAs (40 nM final concentration) using Lipofectamine 2000 according to manufacturer's protocol (Invitrogen). For silencing of ELK4, Dharmacon's (Lafayette, CO, USA) chemically modified ON-TARGETplus siRNAs 5 0 -CGACACAGACATTGATTC ATT-3 0 (ELK4-1) and 5 0 -GAGAATGGAGGGAAAGATAT T-3 0 (ELK4-2) were used (Jackson et al., 2006) , with ONTARGETplus SCR siRNA as a control. For proliferation assays, LNCaP cells were seeded onto 96-well plates (5000 cells per well) in transfection medium. After 24 h, LNCaP cells were transfected with siRNAs (40 nM final concentration) using Lipofectamine 2000 according to manufacturer's protocol (Invitrogen) and the cells were supplemented with 10 nM R1881 or vehicle (ethanol). After 72 and 96 h, samples were analysed using CellTiter96 AQueous cell proliferation assay reagent (Promega) according to manufacturer's instructions. The quantity of formazan reaction product as measured by the absorbance at 492 nm is directly proportional to the number of living cells in culture. In parallel, portions of the cells were collected for qRT-PCR and immunoblotting.
Prostate cancer tissue stainings
Tissue microarrays were prepared as described (Kononen et al., 1998) and analysed using anti-ELK4 antibody. Specificity of ELK4 staining was confirmed by pre-adsorbtion with bacterially produced and purified GST fusion of ELK4 amino acids 154-320 corresponding to the epitope region of the antibody (Supplementary Figure S1) .
